分泌抗 EpCAM 双特异性 T 细胞衔接器的 CAR T 细胞克服靶向上皮来源癌时的肿瘤异质性
CAR T cells secreting anti-EpCAM bispecific T cell engagers overcome tumor heterogeneity in targeting epithelial-originated carcinomas.
嵌合抗原受体(CAR)T细胞疗法治疗实体瘤的成功有限,部分原因是肿瘤异质性和抗原逃逸。
ALL SOURCES
CAR T cells secreting anti-EpCAM bispecific T cell engagers overcome tumor heterogeneity in targeting epithelial-originated carcinomas.
嵌合抗原受体(CAR)T细胞疗法治疗实体瘤的成功有限,部分原因是肿瘤异质性和抗原逃逸。
Glypican-3-targeted therapy in hepatocellular carcinoma: biological insights and therapeutic strategies.
Glypican-3 (GPC3) 是一种癌胚细胞表面蛋白聚糖,在肝细胞癌 (HCC) 中高表达,而在正常成人组织中基本不表达,使其成为基因和细胞治疗的有吸引力的靶点。
Advancing liver cancer treatment with dual-targeting CAR-T therapy.
靶向磷脂酰肌醇蛋白聚糖-3(GPC3)的嵌合抗原受体(CAR)-T细胞疗法在肝细胞癌(HCC)治疗中已显示出前景。
Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody.
使用针对VEGF或VEGFR2的特异性抗体阻断VEGF,可增加TME中的HEV和细胞毒性CD8(+) TIL,在临床前模型中显著提高EAT策略的治疗效果,支持进一步研究VEGF阻断以增强基于BsAb的T细胞免疫疗法的临床研究。
Glypican 3-targeted chimeric antigen receptor T cells secreting TROP2-directed bispecific T cell engagers exhibit potent efficacy against lung squamou
本研究表明,GPC3 CAR-T。
Research progress of drugs targeting GPC3 in cancer therapy.
Glypican-3 (GPC3) 是一种细胞表面硫酸乙酰肝素蛋白聚糖,在正常成人组织中沉默,但在几种癌症中异常重新表达,尤其是肝细胞癌 (HCC)。
Targeted delivery of IFN-α-anti-GPC3 fusion protein via mRNA-LNP platform elicits potent anti-tumor immunity in hepatocellular carcinoma.
重复给药(6 或 10 mpk)确定了最大耐受剂量(MTD)为 6 mpk,至少比最小有效剂量(MED,0.15 mpk)高 40 倍。
Targeting CD16A on NK cells and GPC3 in hepatocellular carcinoma: development and functional validation of a therapeutic bispecific antibody.
本研究引入了三项创新:(1) 一种克服多态性限制的物种特异性 CD16A 结合剂,(2) Fc 结构域工程化改造 (N297A) 以优化稳定性和安全性,以及 (3) 与索拉非尼的协同联合策略。这些结果为 GPC3+ 实体瘤免疫治疗提供了一个可转化的框架。
A conceptual exploration on the synergistic anti-tumor effects of high-order combination of OHSV2-DSTE(FAP5/CD3), CAR-T cells, and immunotoxins in hep
这种高阶联合代表了一种针对肝细胞癌的新型多波次免疫治疗策略。
Integrated Imaging Probe and Bispecific Antibody Development Enables In Vivo Targeting of Glypican-3-Expressing Hepatocellular Carcinoma.
这些数据表明,使用源自小肽的 GPC3/CD3 TRAB 靶向 HCC 细胞,能够在体外和体内有效激活 T 细胞并诱导针对 GPC3+ HCC 肿瘤细胞的细胞毒性反应。
MEMBER ACCOUNT
登录成功会直接打开下一页。